

## MATERIAL DATA SHEET

## Recombinant Human Ataxin-3 Like Cat. # E-343

Ataxin-3-Like protein, also known as Machado-Joseph Disease (MJD) Protein-1-Like, is a 355 amino acid deubiquitinating (DUB) enzyme with a predicted molecular weight of 41 kDa. Full-length Ataxin-3-L contains an N-terminal Joesephin Domain, two Ubiquitin-Interacting-Motifs (UIM's) and a C-terminus consisting of a polyglutamine stretch and tail. Ataxin-3-L targets include Kruppel-Like Factor 5 (KLF5). KLF5 has been reported to promote breast cell proliferation, survival and tumorigenesis. Ubiquitination and proteasome-mediated degradation of KLF5 is antagonized by Ataxin-3-L, suggesting that inhibition of this DUB might provide a target for therapeutic intervention in breast cancer. Ataxin-3 and Ataxin-3-L have been reported to cleave both K48- and K63-linked poly-Ubiquitin in vitro, though enzyme activity in such assays is inefficient when using shorter chain lengths (≤ 6). Ataxin-3-L activity can be efficiently monitored with K63-linked tetra-Ubiquitin Rhodamine (UC-355) substrate.

**Product Information** 

**Quantity:** 50 μg

**MW:** 42 kDa

**Source:** Spodoptera frugiperda, Sf 21 (baculovirus)-derived

Accession # ATXN3L

Contains a C-terminal 6His tag

Stock: X mg/ml (X  $\mu$ M) in 50 mM HEPES pH 7.5, 100 mM NaCl, 10% (v/v) Glycerol,

1 mM TCEP

**Purity:** >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal

Coomassie® Blue stain.

**Use & Storage** 

**Use:** Recombinant Human His6-Ataxin-3-Like protein is a Ubiquitin-specific

deconjugating enzyme. Reaction conditions will need to be optimized for each specific application. We recommend an initial His6-Ataxin-3-like concentration of 10-100 nM when utilizing K63-linked tetra-Ubiquitin Rhodamine (UC-355). Higher

concentrations may be required for other substrates.

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

• 12 months from date of receipt, -70 °C as supplied.

• 3 months, -70 °C under sterile conditions after opening.

Rev. 3/15/2017 Page 1 of 2



An R&D Systems Company

## Literature

## **References:**

- 1. Albrecht, M. et al. (2004) Eur. J. Biochem. 271: 3155
- 2. Bettencourt, C. & M. Lima (2011) Orphanet. J. Rare Dis. 6:35
- 3. Ge, F. et al. (2015) Oncotarget 6: 21369
- 4. Giuseppe, N. et al. (2010) PLoS 5: 10.1371/journal.pone.0012430
- 5. Rodrigues, A.J. et al. (2007) FASEB J. 21: 1126
- 6. Scaglione, K.M. et al. (2011) Mol. Cell. 43: 599
- 7. Todi, S.V. et al. (2009) EMBO J. 28: 372

For research use only. Not for use in humans.

Rev. 3/15/2017 Page 2 of 2